TREATMENT AND OUTCOMES OF STAGE II COLON CANCER IN ALEXANDRIA ONCOLOGY DEPARTMENT IN VIEW OF INTERNATIONAL GUIDELINES

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of Oncology and Nuclear Medicine , Faculty of Medicine, Alexandria University

2 Department of Clinical Oncology and Nuclear Medicine*, Faculty of Medicine, Alexandria University

3 Department of Clinical Oncology,* Faculty of Medicine, Alexandria University

Abstract

INTRODUCTION
Colorectal cancer incidence and mortality rates continue to rise each year and it is now the third most prevalent cancer worldwide behind breast and lung cancer. Stage II colon cancer (CC) represents an early stage of the disease and despite the high cure rates (approximately 80%) with surgery alone, it remains a heterogeneous entity with specific clinico-pathological features increasing the risk of disease recurrence and affecting overall survival (OS) outcomes. Until conclusive randomized control data and strong supporting evidence and biomarkers are available, the postoperative recommendations remain broad, each with concomitant risks. They include observation, adjuvant chemotherapy with 5FU monotherapy or with oxaliplatin-containing doublet therapy based on risk stratification and microsatellite instability (MSI) status. In order to understand current adjuvant therapy utilization, identify treatment gaps and ultimately improve patient outcomes, it is important to evaluate institutional recommendations against real-world data to determine if they continue to be relevant and whether the clinical practice is consistent with international guidelines.

AIM OF THE WORK
The aim of this study was to review the demographic and clinicopathological features influencing outcomes of stage II CC patients presenting to the Alexandria Oncology and Nuclear Medicine Department. The primary objective was to assess the adjuvant chemotherapeutic treatment options delivered to these patients based on risk stratification (low, intermediate and high risk) and compare the chemotherapeutic protocols offered with international guidelines; with 2-year disease-free survival (DFS) as the secondary endpoint.

Keywords

Files

Share

How to cite

Statistics